We know that the higher the potency of the vaccine, the better the immunization effect. Currently, the existing international HPV (human papillomavirus) vaccines GARDASIL9 and Huoyancon are the 4-valent vaccine and the 2-valent vaccine, in that order. Last month, the FDA (U.S. Food and Drug Administration) announced on its website that GARDASIL9 (Gadaxiu, a nine-valent recombinant human papillomavirus vaccine) developed by Merck (known as Merck in the U.S. and Canada) was approved to prevent about 90% of cervical cancer and related cancers. GARDASIL, the world’s first human papillomavirus (HPV) vaccine developed by Merck, is a quadrivalent vaccine that targets four types of viruses, HPV-6, HPV-11, HPV-16 and HPV-18, of which HPV-16 and HPV-18 are the high-risk types that cause cervical cancer. HPV-16 and HPV-18 are the high-risk types of HPV that cause cervical cancer; and was marketed in the U.S. in 2006 through the U.S. Food and Drug Administration (FDA) for priority approval. This vaccine can prevent 70% of cervical cancers. According to Associate Professor Chen Zhiliao of the Department of Obstetrics and Gynecology at Sun Yat Sen Memorial Hospital of Sun Yat-sen University, the HPV vaccine prevents human papillomavirus (HPV) from mutating in the human body. The mutated HPV not only causes cervical cancer in women, but also other reproductive system diseases, including men, such as condyloma acuminatum which is an infection of the human papilloma virus, and cancers associated with men such as anal cancer, penile cancer and prostate cancer. The HPV vaccine is also known as the “cervical cancer vaccine” as it is currently advertised to prevent cervical cancer. The vaccine has been on the market for many years, but it has not been approved in mainland China, so many consumers choose to go to Hong Kong for injection. GARDASIL9 is approved for women aged 9 to 26 years and men aged 9 to 15 years to prevent cervical, vulvar, vaginal and anal cancers caused by HPV (human papillomavirus) types 16, 18, 31, 33, 45, 52 and 58, as well as genital warts caused by HPV types 6 and 11. The new vaccine has the potential to prevent approximately 90% of cervical, vulvar, vaginal, and anal cancers. Compared to the first-generation GARDASIL vaccine, GARDASIL9 adds five additional viral subtypes – 31, 33, 45, 52 and 58 – that cause about 20 percent of cervical cancers that were not prevented by previously FDA-approved HPV virus vaccines. A vaccine that reduces the risk of developing the vast majority of cervical, genital and anal cancers caused by HPV is a critical public health prevention and control tool, and GARDASIL9 provides better protection for the general public,” said Dr. Karen Midthun, director of the FDA’s Center for Biologics Evaluation and Research. “